Clinical Trial

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-06.
Trial Details
NCT Number NCT05773937
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Advanced Malignant Solid Tumors
Enrollment 40 participants
Start Date 2022-06-21
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19